US 12,350,265 B2
Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
In Hwan Bae, Hwaseong-si (KR); Ji Young Song, Hwaseong-si (KR); Jae Yul Choi, Hwaseong-si (KR); and Young Gil Ahn, Hwaseong-si (KR)
Assigned to Hanmi Pharm. Co., Ltd., Hwaseong-si (KR)
Appl. No. 17/622,389
Filed by Hanmi Pharm. Co., Ltd., Hwaseong-si (KR)
PCT Filed Jun. 25, 2020, PCT No. PCT/KR2020/008258
§ 371(c)(1), (2) Date Dec. 23, 2021,
PCT Pub. No. WO2020/262974, PCT Pub. Date Dec. 30, 2020.
Claims priority of application No. 10-2019-0077302 (KR), filed on Jun. 27, 2019.
Prior Publication US 2022/0354842 A1, Nov. 10, 2022
Int. Cl. A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 31/506 (2013.01); A61P 35/02 (2018.01)] 21 Claims
 
1. A pharmaceutical combination comprising a compound of Formula 1, a stereoisomer thereof, a tautomer thereof, or a combination thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and
one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or solvate thereof; wherein:

OG Complex Work Unit Chemistry
in Formula 1,
Ea is hydrogen, hydroxy or C1-4 alkoxy;
Eb is hydrogen, halogen, C1-4 alkyl or C1-4 fluoroalkyl;
Ec and Ed are independently of each other hydrogen or hydroxy;
X′ is hydrogen or hydroxy;
k is an integer from 1 to 2;
each Q is independently of the other hydroxy, halogen, C1-4 alkyl, hydroxyC1-4 alkyl or C1-4 alkoxy;
Z′ is a monovalent functional group shown in formula (2);

OG Complex Work Unit Chemistry
in this case, in Formula 2, n is an integer of 1 to 2;
each A is, independently of the other, a functional group selected from hydroxy, C1-4 alkyl and hydroxyC1-4 alkyl, wherein at least one A is C1-4 alkyl; and
L is hydrogen, C1-4 alkyl, hydroxy or hydroxy C1-4 alkyl.